Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 1667 results found since Jan 2013.

Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway
AbstractThe aberrantly up-regulated CDK9 can be targeted for cancer therapy. The CDK inhibitor dinaciclib (Dina) has been found to drastically sensitizes cancer response to TRAIL-expressing extracellular vesicle (EV-T). However, the low selectivity of Dina has limited its application for cancer. We propose that CDK9-targeted siRNA (siCDK9) may be a good alternative to Dina. The siCDK9 molecules were encapsulated into EV-Ts to prepare a complexed nanodrug (siEV-T). It was shown to efficiently suppress CDK9 expression and overcome TRAIL resistance to induce strikingly augmented apoptosis in lung cancer both in vitro and in v...
Source: Apoptosis - April 15, 2023 Category: Molecular Biology Source Type: research

The kinesin light chain ‐2, a target of mRNA stabilizing protein HuR, inhibits p53 protein phosphorylation to promote radioresistance in NSCLC
ConclusionTaken together, these results indicated that HuR-KLC2 forms a positive feedback loop, which decreases the phosphorylation of p53 and thereby weaken the radiosensitivity of lung cancer cells. Our findings highlight the potential prognosis and therapeutic target value of KLC2 in lung cancer patients treated with radiotherapy.
Source: Thoracic Cancer - April 14, 2023 Category: Cancer & Oncology Authors: Simiao Qiao, Yuhang Jiang, Na Li, Xiaoxia Zhu Tags: ORIGINAL ARTICLE Source Type: research

PYCR1 promotes the malignant progression of lung cancer through the JAK-STAT3 signaling pathway via PRODH-dependent glutamine synthesize
CONCLUSION: PYCR1 has certain value in the diagnosis and prognosis of lung cancer. Moreover, through regulating JAK-STAT3 signaling pathway, PYCR1 significantly participated in process of lung cancer progression via the metabolism link between proline and glutamine, indicating that PYCR1 might be also a novel therapeutic target.PMID:37018868 | DOI:10.1016/j.tranon.2023.101667
Source: Translational Oncology - April 5, 2023 Category: Cancer & Oncology Authors: Lihong Zhang Xinyu Zhao Enqin Wang Ye Yang Liangfeng Hu Hongkun Xu Baojun Zhang Source Type: research

Targeting Rab26 to Conquer Cisplatin-Resistant Lung Cancer with Self-Assembled DNA Nanomaterials
In this study, we developed a nanosystem based on programmed DNA self-assembly of Rab26 siRNA-loaded nanoparticles (siRNP). We demonstrated that siRNP could be effectively transfected into cisplatin-resistant A549 (A549/DDP) cells. These siRab26-carrying nanoparticles induced apoptosis and inhibited the disruption of autophagy. The combination therapy of siRab26 knockdown with cisplatin could improve the antitumor therapy compared with a single one in vitro. In nude mice, siRNP enhanced the chemosensitivity of cisplatin-resistant cells and inhibited tumor xenograft development. These outcomes suggest that siRNP is an effec...
Source: Biomacromolecules - April 3, 2023 Category: Biochemistry Authors: Beinuo Wang Ruijie Zhang Yao Wang Hang Qian Di Wu Binfeng He Hu Liao Source Type: research

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highligh...
Source: Frontiers in Pharmacology - March 24, 2023 Category: Drugs & Pharmacology Source Type: research

ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis
CONCLUSIONS: Our results show that anchorage-independent survival and growth of cancer cells are supported by changes in genes and proteins that drive glucose metabolism towards an enhanced lactate production. Notably, this finding is valid for all lung and breast cancer cell lines we have analyzed in different nutrient environmental conditions. broader Validation of this mechanism in other cancer cells of different origin will be necessary to broaden the role of ALDOC and ENO2 to other tumor types. Future in vivo studies will be necessary to assess the role of ALDOC and ENO2 in cancer metastasis.PMID:36945054 | DOI:10.1186/s13046-023-02641-0
Source: Clinical Lung Cancer - March 22, 2023 Category: Cancer & Oncology Authors: Claudia De Vitis Anna Martina Battaglia Matteo Pallocca Gianluca Santamaria Maria Chiara Mimmi Alessandro Sacco Francesca De Nicola Marco Gaspari Valentina Salvati Francesca Ascenzi Sara Bruschini Antonella Esposito Giulia Ricci Eleonora Sperandio Alice M Source Type: research

The Biological Role of Lncrna SNHG6 in Non-Small Cell Lung Cancer Cells Via Targeting P21
CONCLUSION: Silencing lncRNA SNHG6 represses the proliferation and facilitates the apoptosis of NSCLC cells through regulating p21.PMID:36933244
Source: Alternative Therapies in Health and Medicine - March 18, 2023 Category: Complementary Medicine Authors: Yongjie Li Dunzhi Fu Wei Sun Qixing Yan Xiaopeng Bu Zhongkai Liao Fu Li Source Type: research